REG3A and Insulin resistance: The direct systemic activity on insulin resistance, including its impact on muscle glucose uptake and fat/lean mass reduction, as well as the activity in modulating the gut microbiome17, suggest that REG3A may be a therapeutic approach complementary to existing treatments for type 2 diabetes, such as metformin and GLP1 agonists.